Ambrosy AP, von Haehling S, Kalra PR, et al. - Researchers undertook this randomized, open-label, multicenter clinical trial (FERWON-NEPHRO) to assess safety as well as efficacy of a single infusion of ferric derisomaltose (FDI; an intravenous high-dose iron formulation) 1,000 mg vs up to 5 doses of iron sucrose (IS) 200 mg (recommended cumulative dose, 1,000 mg) over 8 weeks in patients suffering from non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anemia. There were 1,525 patients in the safety analysis, of whom 244 (16%) had a history of heart failure (HF). Findings showed not only the safety and good tolerability of a single infusion of FDI in NDD-CKD cases but also fewer cardiovascular adverse events and a faster hematological response conferred by this treatment, relative to multiple doses of IS. These impacts were shown to be similar for cases with and without HF.